Ken Griffin Point Biopharma Global Inc. Transaction History

Citadel Advisors LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$6.67 - $9.71 $1.99 Million - $2.89 Million	-297,807 Reduced 12.13%	2,157,166 $14.4 Million
Q2 2023 Aug 14, 2023	SELL	$6.86 - $10.86 $5.03 Million - $7.96 Million	-733,055 Reduced 22.99%	2,454,973 $22.2 Million
Q1 2023 May 15, 2023	SELL	$6.78 - $8.1 $430,882 - $514,771	-63,552 Reduced 1.95%	3,188,028 $23.2 Million
Q4 2022 Feb 14, 2023	SELL	$5.72 - $9.78 $2.45 Million - $4.19 Million	-428,417 Reduced 11.64%	3,251,580 $23.7 Million
Q3 2022 Nov 14, 2022	BUY	$7.24 - $10.31 $9.92 Million - $14.1 Million	1,369,820 Added 59.3%	3,679,997 $28.4 Million

20K

Ticker PNT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 104,025,000
Description
POINT Biopharma Global Inc., a radiopharmaceutical company, focuses on the development and commercialization of radioligands that fight cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate canc...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.